top of page

Biopharma Daily Stock Updates - 09/27/21

$XBI $131.91 +1.50%

 

Covid Updates

$NRXP +6.8% NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil). source


$AZN -2.7% AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases. source



Pipeline Updates

$GILD -1.1% Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization source


$ALT +1.50% Altimmune To Announce 12-Week Data From ALT-801 Phase 1 Trial On September 28, 2021 source


$PTN +3.0% Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting. source


$CCXI +5.6% ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis. source


$SRPT +0.6% Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA. source


$ARQT +0.1% New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress. source


$CRTX -1.3% Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021. source


$RFL +2.0% Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif. source


$ATNX +1.9% Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis. source


$ACXP +1.5% Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference. source


$PHAT +3.3% Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®). source


$EVFM +1.8% Evofem Biosciences Announces Publication in Peer-Reviewed Journal Advances in Therapy. source


$OTIC +10.2% Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting. source


$ADCT +4.8% ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors. source


$RGNX +3.1% REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call. source


$BHVN -0.4% Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program. source


$TYME +5.6% TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor. source


$ASLN -34.8% ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis. source


$EVLO +2.3% Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease. source



Finance & Business Updates

$PRTK -2.7% Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax source


$ZIOP +4.4% Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway source

 

Posted by FS/JM

0 comments
bottom of page